中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

炎症反应在慢加急性肝衰竭中的作用及治疗策略

徐华谦 李雪 汤善宏

引用本文:
Citation:

炎症反应在慢加急性肝衰竭中的作用及治疗策略

DOI: 10.3969/j.issn.1001-5256.2022.08.041
基金项目: 

四川省卫生健康委员会科研课题 (20PJ180)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:徐华谦参与拟定写作思路,收集分析文献,论文撰写及修改;李雪参与指导撰写文章及论文修改;汤善宏负责拟定写作思路,指导撰写文章与最后定稿。
详细信息
    通信作者:

    汤善宏,15928956390@163.com

Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure

Research funding: 

Scientific Research Project of Sichuan Provincial Health Commission (20PJ180)

More Information
  • 摘要: 慢加急性肝衰竭(ACLF)是在慢性肝病基础上,由一系列诱因导致肝功能迅速恶化的临床综合征,以多器官衰竭和短期高病死率为突出特征。系统性炎症的发生是ACLF疾病进展的重要影响因素之一,是机体对感染的自然防御,但当炎症介质过度释放打破原有的“促炎和抗炎”动态平衡,反而会加重肝损伤甚至发生失代偿。因此,炎症反应的强度与ACLF患者预后密切相关,但目前对于炎症反应对ACLF患者的影响以及如何应对炎症风暴的关注度还不够,故本文归纳了目前炎症反应对ACLF的影响及其治疗进展,为临床中ACLF的诊疗提供思路。

     

  • [1] SARIN SK, CHOUDHURY A, SHARMA MK, et al. Correction to: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(6): 826-828. DOI: 10.1007/s12072-019-09980-1.
    [2] BAJAJ JS, HEUMAN DM, HYLEMON PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2014, 39(10): 1113-1125. DOI: 10.1111/apt.12695.
    [3] ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74(3): 670-685. DOI: 10.1016/j.jhep.2020.11.048.
    [4] TANG SH, ZENG WZ, JIANG MD, et al. Research progress in prediction of clinical outcome in patients with liver failure[J]. J Clin Hepatol, 2015, 31(1): 135-138. DOI: 10.3969/j.issn.1001-5256.2015.01.031.

    汤善宏, 曾维政, 蒋明德, 等. 肝衰竭患者临床预后判断研究进展[J]. 临床肝胆病杂志, 2015, 31(1): 135-138. DOI: 10.3969/j.issn.1001-5256.2015.01.031.
    [5] ALBILLOS A, de GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003.
    [6] MICHELENA J, ALTAMIRANO J, ABRALDES JG, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis[J]. Hepatology, 2015, 62(3): 762-772. DOI: 10.1002/hep.27779.
    [7] CULLARO G, SHARMA R, TREBICKA J, et al. Precipitants of acute-on-chronic liver failure: an opportunity for preventative measures to improve outcomes[J]. Liver Transpl, 2020, 26(2): 283-293. DOI: 10.1002/lt.25678.
    [8] ZACCHERINI G, WEISS E, MOREAU R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment[J]. JHEP Rep, 2021, 3(1): 100176. DOI: 10.1016/j.jhepr.2020.100176.
    [9] CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
    [10] van WYNGENE L, VANDEWALLE J, LIBERT C. Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last?[J]. EMBO Mol Med, 2018, 10(8): e8712. DOI: 10.15252/emmm.201708712.
    [11] BAJAJ JS, VARGAS HE, REDDY KR, et al. Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2019, 17(4): 756-765. e3. DOI: 10.1016/j.cgh.2018.07.022.
    [12] VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis[J]. J Hepatol, 2021, 75(3): 589-599. DOI: 10.1016/j.jhep.2021.04.022.
    [13] PIANO S, SINGH V, CARACENI P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology, 2019, 156(5): 1368-1380. e10. DOI: 10.1053/j.gastro.2018.12.005.
    [14] FERNÁNDEZ J, ACEVEDO J, WIEST R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67(10): 1870-1880. DOI: 10.1136/gutjnl-2017-314240.
    [15] FERNÁNDEZ J, ANGELI P, TREBICKA J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis[J]. Clin Gastroenterol Hepatol, 2020, 18(4): 963-973. e14. DOI: 10.1016/j.cgh.2019.07.055.
    [16] CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391(10138): 2417-2429. DOI: 10.1016/S0140-6736(18)30840-7.
    [17] FERNÁNDEZ J, CLÀRIA J, AMORÓS A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology, 2019, 157(1): 149-162. DOI: 10.1053/j.gastro.2019.03.021.
    [18] GUSTOT T, JALAN R. Acute-on-chronic liver failure in patients with alcohol-related liver disease[J]. J Hepatol, 2019, 70(2): 319-327. DOI: 10.1016/j.jhep.2018.12.008.
    [19] ARROYO V, MOREAU R, JALAN R. Acute-on-chronic liver failure[J]. N Engl J Med, 2020, 382(22): 2137-2145. DOI: 10.1056/NEJMra1914900.
    [20] ZHANG YC, BI YZ, FANG X, et al. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. J Clin Hepatol, 2019, 35(7): 1570-1575. DOI: 10.3969/j.issn.1001-5256.2019.07.029.

    张永超, 毕研贞, 方萧, 等. 益生菌对慢加急性肝衰竭大鼠模型的保护作用及其机制[J]. 临床肝胆病杂志, 2019, 35(7): 1570-1575. DOI: 10.3969/j.issn.1001-5256.2019.07.029.
    [21] PHILIPS CA, PHADKE N, GANESAN K, et al. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis[J]. Indian J Gastroenterol, 2018, 37(3): 215-225. DOI: 10.1007/s12664-018-0859-4.
    [22] MULLISH BH, MCDONALD J, THURSZ MR, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial[J]. Hepatology, 2017, 66(4): 1354-1355. DOI: 10.1002/hep.29369.
    [23] HARTMANN P, HOCHRATH K, HORVATH A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice[J]. Hepatology, 2018, 67(6): 2150-2166. DOI: 10.1002/hep.29676.
    [24] GOEL A, RAHIM U, NGUYEN LH, et al. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis[J]. Aliment Pharmacol Ther, 2017, 46(11-12): 1029-1036. DOI: 10.1111/apt.14361.
    [25] ACHARYA C, SAHINGUR SE, BAJAJ JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis[J]. JCI Insight, 2017, 2(19): e94416. DOI: 10.1172/jci.insight.94416.
    [26] FISCHER P, STEFANESCU H, HATEGAN R, et al. Bacterial infection-related acute-on-chronic liver failure: The standpoint matters![J]. J Hepatol, 2021, 75(4): 1009-1010. DOI: 10.1016/j.jhep.2021.04.046.
    [27] WU B, DU LY, MA YJ, et al. Effects of different combinations of artificial liver support system on efficacy and inflammatory indexes of patients with hepatitis B virus-related acute-on-chronic liver failure in early and middle stages[J/CD]. Chin J Liver Dis(Electr Version), 2021, 13(1): 32-38. DOI: 10.3969/j.issn.1674-7380.2021.01.006.

    吴蓓, 杜凌遥, 马元吉, 等. 不同组合人工肝支持系统治疗乙型肝炎病毒相关早、中期慢加急性肝衰竭患者的疗效及对炎症指标的影响[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(1): 32-38. DOI: 10.3969/j.issn.1674-7380.2021.01.006.
    [28] GUO X, WU F, GUO W, et al. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure[J]. J Int Med Res, 2020, 48(6): 300060520932053. DOI: 10.1177/0300060520932053.
    [29] MAIWALL R, BAJPAI M, CHOUDHURY AK, et al. Therapeutic plasma-exchange improves systemic inflammation and survival in acute-on-chronic liver failure: A propensity-score matched study from AARC[J]. Liver Int, 2021, 41(5): 1083-1096. DOI: 10.1111/liv.14806.
    [30] SUNDARAM V, JALAN R, WU T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation[J]. Gastroenterology, 2019, 156(5): 1381-1391. e3. DOI: 10.1053/j.gastro.2018.12.007.
    [31] KHANAM A, TREHANPATI N, RIESE P, et al. Blockade of neutrophil's chemokine receptors CXCR1/2 abrogate liver damage in acute-on-chronic liver failure[J]. Front Immunol, 2017, 8: 464. DOI: 10.3389/fimmu.2017.00464.
    [32] ANAND L, BIHARI C, KEDARISETTY CK, et al. Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis[J]. Liver Int, 2019, 39(1): 115-126. DOI: 10.1111/liv.13923.
    [33] ENGELMANN C, MARTINO VD, KERBERT A, et al. The current status of granulocyte-colony stimulating factor to treatacute-on-chronic liver failure[J]. Semin Liver Dis, 2021, 41(3): 298-307. DOI: 10.1055/s-0041-1723034.
    [34] LIN BL, CHEN JF, QIU WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial[J]. Hepatology, 2017, 66(1): 209-219. DOI: 10.1002/hep.29189.
    [35] AHMAD A, WALI AF, REHMAN MU, et al. Therapeutic potential of rhododendron arboreum polysaccharides in an animal model of lipopolysaccharide-inflicted oxidative stress and systemic inflammation[J]. Molecules, 2020, 25(24): 6045. DOI: 10.3390/molecules25246045.
    [36] WANG X, SUN M, YANG X, et al. Value of liver regeneration in predicting short-term prognosis for patients with hepatitis B-related acute-on-chronic liver failure[J]. Biomed Res Int, 2020, 2020(4): 1-7. DOI: 10.1155/2020/5062873.
  • 加载中
计量
  • 文章访问数:  524
  • HTML全文浏览量:  96
  • PDF下载量:  78
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-12-29
  • 录用日期:  2022-02-17
  • 出版日期:  2022-08-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回